Coronary disease & ACSRandomised controlled trial
Titanium-Nitride-Oxide–Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome
- Randomised controlled trial
- multicentre
- open-label
- 12 sites in 5 European countries
- long-term follow-up report
Authors' conclusion
In this study, patients with ACS had a main composite outcome that was not different 5 years after TiNO-coated stent or EES.
Study context
- Population
- Patients with acute coronary syndrome (ACS) (STEMI, NSTEMI, unstable angina) with ≥1 de novo lesion
- Participants
- 1,491 patients
- Comparison
- Titanium-nitride-oxide (TiNO)-coated stent vs everolimus-eluting stent (EES)
- TiNOn = 989
- EESn = 502reference
- Primary endpoint
- Main composite outcome:
- Cardiac death
- Myocardial infarction (MI)
- Ischemia-driven target lesion revascularization (trial primary end point assessed at 12 months)
- Follow-up
- 5 years
Primary result
Main composite outcome
Hazard ratio
0.94
95% CI 0.69–1.28
P = 0.69
Events by treatment group
TiNO vs EES
HR 0.94 (95% CI 0.69–1.28); P = 0.69
As reported in the abstract
Further findings
| Outcome | TiNO | EES | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Cardiac death · 5 years | 0.9% | 3.0% | 0.30 (0.13–0.69) | P = 0.005 | |
| MI · 5 years | 4.6% | 7.0% | 0.64 (0.41–0.99) | P = 0.049 | |
| Target lesion revascularization · 5 years | 7.4% | 6.4% | 1.16 (0.77–1.76) | P = 0.47 | |
| 0.10.31310Hazard ratio (log scale) |
Safety
| Outcome | TiNO | EES | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Stent thrombosis · 5 years | 1.2% | 2.8% | 0.43 (0.20–0.93) | P = 0.034 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Titanium-Nitride-Oxide–Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome. JAMA Cardiol. Published 1 July 2023. doi:10.1001/jamacardio.2023.1373
Summarised from the published abstract; every number is checked against it